Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Questcor Pharmaceuticals Inc    QCOR

Delayed Quote. Delayed  - 08/14 04:00:01 pm
93.6 USD   +1.65%
2015DJMallinckrodt Tops Expectations
2015DJMallinckrodt Increases Buyback Program
2015 Citron's Left discloses short position in Mallinckrodt
News SummaryMost relevantAll newsSector news 

Questcor Pharmaceuticals, Inc. : Questcor Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

01/03/2013 | 06:35am US/Eastern

ANAHEIM, Calif., Jan. 3, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management is scheduled to present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Thursday, January 10, 2013 at 9:00 a.m. PT / 12:00 p.m. ET.

A live webcast with accompanying slide presentation, and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm. The replay will be available for approximately 90 days after the event.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor's primary product is H.P. Acthar(®) Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of proteinuria in idiopathic types of nephrotic syndrome, the treatment of acute exacerbations of multiple sclerosis in adults, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor has also launched a pilot effort in rheumatology, as Acthar is approved for several rheumatology-related conditions including Dermatomyositis, Polymyositis, Lupus and Rheumatoid Arthritis. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. For more information about Questcor, please visit www.questcor.com.

SOURCE Questcor Pharmaceuticals, Inc.

React to this article
2015DJMallinckrodt Tops Expectations
2015DJMallinckrodt Increases Buyback Program
2015 Citron's Left discloses short position in Mallinckrodt
2015DJMallinckrodt to Buy Immunotherapy Firm Therakos
2015DJMallinckrodt Earnings Soar on Acquisitions -- 2nd Update
2015DJMallinckrodt Earnings Soar on Acquisitions -- Update
2015DJMallinckrodt Earnings Soar on Acquisitions
2014DJMallinckrodt Sales Surge on Acquisitions in Specialty Pharma Segment
2014DJJOHN PAULSON : Paulson & Co. Opens Positions in Covidien, DirecTV and Allergan
2014DJGreenlight Notes Short Positions in Safeway, Lorillard -Reuters